艾滋病毒状况和查尔森并发症指数对病例控制研究中的COVID-19临床结果的影响
Rebecca C Gerrity1, Melissa Parkinson1, Rachel Strength1
1From the Department of Medicine.
与对照组相比,携带艾滋病毒的人 (PLWH) 的COVID-19结果与对照组相似. 然而,高查尔森并发症指数得分显著增加了所有患者的发病率和死亡率,无论艾滋病毒状况如何.
科学领域:
- 传染性疾病 传染性疾病
- 公共卫生 公共卫生
- 病毒学 病毒学
背景情况:
- 在COVID-19大流行期间,共患病被强调为严重疾病和死亡的风险因素.
- 关于人类免疫缺陷病毒 (HIV) 同感染对COVID-19结果的影响的研究有限.
- 了解这些结果对于在全球卫生危机期间管理脆弱人群至关重要.
研究的目的:
- 为了比较艾滋病毒感染的COVID-19患者与没有艾滋病毒的匹配对照组的临床结果.
- 调查艾滋病毒状况对COVID-19相关发病率和死亡率的具体影响.
- 评估伴随性疾病的影响,如高的查尔森伴随性疾病指数,在PLWH中对COVID-19结果的影响.
主要方法:
- 确定了45名艾滋病毒感染者 (PLWH) 住院接受COVID-19治疗的队列.
- PLWH与没有艾滋病毒病史的COVID-19阳性患者匹配1: 1.
- 匹配组之间的临床结果进行了比较,敏感性分析排除了9对不匹配的对.
主要成果:
- 在PLWH和对照组之间没有观察到人口统计变量或测量的临床结果的显著差异.
- 低于200细胞/μL的CD4计数与增加的发病率或死亡率无关.
- 查尔森并发症指数得分高 (>3) 与输管治疗,血管压缩剂使用,ICU入院,死亡率和更长时间住院时间的增加显著相关,无论艾滋病毒状况如何.
结论:
- 与匹配的对照组相比,仅仅艾滋病毒状况并没有显著改变COVID-19的结果.
- 查尔森并发症指数成为严重COVID-19结果的关键预测指标.
- 管理伴随性疾病对于改善COVID-19预后至关重要,特别是在具有潜在健康状况的个体中.
更多相关视频
08:14An In Vitro Model for Measuring Immune Responses to Malaria in the Context of HIV Co-infection
Published on: October 6, 2015
14:23A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses
Published on: August 31, 2014
相关概念视频
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Factors Affecting Illness
For instance, risk factors are connected to illness,...
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Retrovirus Life Cycles
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
